Series B - Jnana Therapeutics - 2021-08-18 - Crunchbase

Aug 18, 2021  · Jnana Therapeutics raised $50000000 on 2021-08-18 in Series B. Search Crunchbase ... Save . Summary. Overview. Edit Overview Section. Organization Name . …


Install CouponFollow Chrome Extension   CouponFollow Extension

$50000000
OFF

Series B - Jnana Therapeutics - 2021-08-18 - Crunchbase

6 days from now

Aug 18, 2021  · Jnana Therapeutics raised $50000000 on 2021-08-18 in Series B. Search Crunchbase ... Save . Summary. Overview. Edit Overview Section. Organization Name . …

crunchbase.com

$50
OFF

Jnana Therapeutics Closes $50 Million Series B Financing To …

6 days from now

Boston, Mass., August, 18, 2021 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but …

jnanatx.com

$50
OFF

Jnana Therapeutics Closes $50M Series B Financing - FinSMEs

6 days from now

Aug 20, 2021  · Jnana Therapeutics, a Boston, Mass.-based biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated …

finsmes.com

$50
OFF

Jnana Therapeutics Secures $50 Mln Investment In Series B Led By …

6 days from now

Aug 22, 2021  · Based on chemical proteins, Jnana focuses on SLC transporters and other difficult-to-use drugs. Ph.D., Co-Founder, CEO and President of Jnana Therapeutics Joanne …

gritdaily.com

$50
OFF

Jnana Therapeutics Picks Up $50m Series B - Venture Capital Journal

6 days from now

Aug 18, 2021  · Jnana Therapeutics picks up $50m Series B. Jnana Therapeutics, a biotechnology company, has secured $50 million in Series B financing. Iris Dorbian - 18 August 2021. Share …

venturecapitaljournal.com

$50
OFF

Jnana Therapeutics Brings In $50M Series B - PitchBook

6 days from now

Aug 19, 2021  · Jnana Therapeutics has raised $50 million in a round led by RA Capital Management.The Boston-based company's drug discovery platform targets specific transport …

pitchbook.com

$50
OFF

Jnana Closes $50M Series B Round, Picks PKU As Lead Indication

6 days from now

Aug 18, 2021  · Jnana Therapeutics Inc. closed a $50 million series B round and took the covers off its lead program, a small-molecule inhibitor of the solute carrier (SLC) transporter …

bioworld.com

$50
OFF

Jnana Therapeutics Closes $50 Million Series B Financing To …

6 days from now

Aug 18, 2021  · BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well …

pharmiweb.com

$107
OFF

Jnana Therapeutics Brings In $107M Funds, $2B Roche Collab

6 days from now

Nov 15, 2022  · Jnana tops up with $107M series C, $2B Roche deal as it pushes metabolic asset into clinic. Jnana Therapeutics is hitting early-stage momentum, adding additional validation in …

fiercebiotech.com

$265000000
OFF

Series B - Sonoma BioTherapeutics - 2021-08-04 - Crunchbase

6 days from now

Aug 4, 2021  · Sonoma BioTherapeutics raised $265000000 on 2021-08-04 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. ... Organization Name . Sonoma …

crunchbase.com

$107
OFF

Jnana Therapeutics Raises $107 Million To Advance Lead PKU …

6 days from now

Nov 15, 2022  · Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of …

prnewswire.com

$107
OFF

Jnana Therapeutics Raises $107 Million To Advance Lead PKU …

6 days from now

Nov 15, 2022  · Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana’s Board of …

jnanatx.com

$61000000
OFF

Series B - Mahana Therapeutics - 2021-08-11 - Crunchbase

6 days from now

Aug 11, 2021  · Mahana Therapeutics raised $61000000 on 2021-08-11 in Series B. Start Free Trial . Chrome Extension

crunchbase.com

$107
OFF

Series C - Jnana Therapeutics - 2022-11-15 - Crunchbase Funding …

6 days from now

News • Nov 15, 2022. Fierce Biotech — Jnana tops up with $107M series C, $2B Roche deal as it pushes metabolic asset into clinic. News • Nov 15, 2022. Jnana Therapeutics — Jnana …

crunchbase.com

$20000000
OFF

Series B - Chase Therapeutics - 2021-10-20 - Crunchbase

6 days from now

Oct 20, 2021  · Chase Therapeutics raised $20000000 on 2021-10-20 in Series B. Search Crunchbase. Start Free Trial ... Save . Summary. Overview. Edit Overview Section. …

crunchbase.com

FAQs about Series B - Jnana Therapeutics - 2021-08-18 - Crunchbase Coupon?

How many investors does Jnana Therapeutics have?

Jnana Therapeutics has 8 investors including AbbVie Biotech Ventures and Avalon Ventures. How much funding has Jnana Therapeutics raised to date? Jnana Therapeutics has raised . When was the last funding round for Jnana Therapeutics? Jnana Therapeutics closed its last funding round on Nov 15, 2022 from a Series C round. ...

Does Jnana Therapeutics have A chemoproteomic platform?

BOSTON-- ( BUSINESS WIRE )-- Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, today announced the closing of a $50 million Series B financing. ...

Who is Jnana Therapeutics?

Jnana Therapeutics is a biotechnology company utilizing a next generation chemoproteomic platform to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. ...

When did Jnana Therapeutics close?

Jnana Therapeutics closed its last funding round on Nov 15, 2022 from a Series C round. Who are Jnana Therapeutics's competitors? Alternatives and possible competitors to Jnana Therapeutics may include Carisma Therapeutics , Interius BioTherapeutics , and Cedilla Therapeutics. ...

Is Jnana a good company?

“Jnana is pioneering the discovery of small-molecule medicines targeting difficult-to-drug targets, including SLC transporters—a target class that has been highly challenging to drug, yet offers significant therapeutic potential,” said Matthew Hammond, Ph.D., Principal at RA Capital and now a member of Jnana’s Board of Directors. ...

Who is Jnana?

Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures and AbbVie Ventures. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension